Literature DB >> 12932637

Subcellular trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma cells.

Aparna Nori1, Keith D Jensen, Monica Tijerina, Pavla Kopecková, Jindrich Kopecek.   

Abstract

One of the main obstacles to efficient intracellular delivery of therapeutic macromolecules is the barrier posed by the plasma membrane. In this study, the cell penetrating peptide Tat was conjugated to a synthetic macromolecule based on N-(2-hydroxypropyl)methacrylamide (HPMA) and its subcellular distribution in human ovarian carcinoma cell lines was studied. The Tat peptide mediated uptake resulted in cytoplasmic and nuclear localization and was found to be energy independent. Time and concentration studies verified the rapidity and dependence of the transport process on these parameters. Enhanced uptake of a polymer bound anticancer drug doxorubicin was also demonstrated. These results were corroborated independently by subcellular fractionation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932637     DOI: 10.1016/s0168-3659(03)00213-x

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  14 in total

Review 1.  Controlling subcellular delivery to optimize therapeutic effect.

Authors:  Mohanad Mossalam; Andrew S Dixon; Carol S Lim
Journal:  Ther Deliv       Date:  2010-07

2.  Guanidine-Containing Methacrylamide (Co)polymers via aRAFT: Toward a Cell Penetrating Peptide Mimic().

Authors:  Nicolas J Treat; Deedee Smith; Chengwen Teng; Joel D Flores; Brooks A Abel; Adam W York; Faqing Huang; Charles L McCormick
Journal:  ACS Macro Lett       Date:  2011-11-21       Impact factor: 6.903

3.  Semitelechelic HPMA copolymers functionalized with triphenylphosphonium as drug carriers for membrane transduction and mitochondrial localization.

Authors:  Jon Callahan; Jindrich Kopecek
Journal:  Biomacromolecules       Date:  2006-08       Impact factor: 6.988

4.  A biodegradable pH-sensitive micelle system for targeting acidic solid tumors.

Authors:  Vijay A Sethuraman; Myung Cheon Lee; You Han Bae
Journal:  Pharm Res       Date:  2007-11-13       Impact factor: 4.200

5.  L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).

Authors:  Young Min Kwon; Hee Sun Chung; Cheol Moon; James Yockman; Yoon Jeong Park; Scott D Gitlin; Allan E David; Victor C Yang
Journal:  J Control Release       Date:  2009-07-03       Impact factor: 9.776

Review 6.  Protein- and peptide-modified synthetic polymeric biomaterials.

Authors:  Ohm D Krishna; Kristi L Kiick
Journal:  Biopolymers       Date:  2010       Impact factor: 2.505

7.  The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells.

Authors:  Rupa R Sawant; Rishikesh M Sawant; Amit A Kale; Vladimir P Torchilin
Journal:  J Drug Target       Date:  2008-08       Impact factor: 5.121

8.  Facile Synthesis of PEGylated PLGA Nanoparticles Encapsulating Doxorubicin and its In Vitro Evaluation as Potent Drug Delivery Vehicle.

Authors:  Rajiv Kumar; Apurva Kulkarni; Jude Nabulsi; Dattatri K Nagesha; Robert Cormack; Mike G Makrigiorgos; Srinivas Sridhar
Journal:  Drug Deliv Transl Res       Date:  2013-08-01       Impact factor: 4.617

Review 9.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging.

Authors:  Vladimir P Torchilin
Journal:  AAPS J       Date:  2007-05-11       Impact factor: 4.009

10.  PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation.

Authors:  Young Min Kwon; Yong Tao Li; Jun F Liang; Yoon Jeong Park; Li-Chien Chang; Victor C Yang
Journal:  J Control Release       Date:  2008-06-26       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.